With over 174,000 new cases of lung cancer being diagnosed in the United States each year novel chemotherapy treatments with efficacy towards both small-cell and non-small cell lung carcinoma is of interest to increase the survival rate of cancer patients.
Introduction
This project was designed around structural understanding and pharmaceutical engineering of the EGFR kinase. Epithelial Growth Factor (EGF) is a growth factor is that is expressed for the normal growth of epithelial cells as linings of cavities and surfaces inside the body. The EGFR is the receptor which is activated by the EGF to initiate epithelial propagation. Under normal circumstances the EGF -EGFR complex is initiated under growth conditions however overexpression or stimulation by cancer cells can cause or promote unchecked cellular proliferation (i.e. cancer). This research sought to understand the blockade of the EGFR to inhibit lung cancer formation.
Specific and Overall Goal
The overall goal is to investigate the interaction of multiple drug candidates to find the best structural motifs for targeted inhibition of the EGFR kinase moiety. This research will first determine the binding and chemical properties of the EGFR active site molecules as a control group. Secondly, a group of select drug candidates whose properties are more effective at binding to the active site versus the control molecules will be chosen. Drug classification analysis will indicate preferences to improved active site binding. Finally, quantitative structure and activity relationship (QSAR) analysis will be done on both the control and experimental molecules to identify similar trends and values.
Methods and Materials
22 isoforms of EGFR that contained active site molecules were selected from the RCSB protein databank. The EGFR active site molecules were considered as controls versus drug candidates. 715 FDA approved pharmaceuticals were selected and computationally bound to the PI3K kinase protein using IGEMDock. The 22 protein values were averaged for all 715 drug candidates and control molecules. IGEMDock used two independent docking with the average of both bindings factoring into binding selectivity. An ANOVA was done to determine if any discrepancies in binding were seen between proteins. The best 10 grouping based on binding energies was selected and structural data such as molecular weight and partition coefficient was collected using Dragon and compared to control molecules. 
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Discussion
Upon analysis of the data, multiple compounds were identified as effective based upon their interactions with each protein. An ANOVA determination of differences between the 22 proteins analyzed indicated a statistical difference was seen. Specifically an average energy of -111.563 was found for the drug candidates compared to -96.6663for the control molecules. 10 drug candidates were chosen due to their low binding energies (for both binding interactions). An ANOVA determination of differences between the 22 proteins analyzed indicated a statistical difference was seen with an F value of 5.97267 compared to an F critical value of 1.55612. Structural analysis found that many of these molecules are relatively small with similar partition coefficient (-0.009 to 0.3.72) of the top binders when compared to control molecules.
Conclusion
By using the computational techniques we were able to identify several molecule that show improved binding efficacy over currently used EGFR inhibitors. These EGFR drug candidates indicated a diverse pool of EGFR binders with improved efficacy. This work can be used to engineer these motifs into novel EGFR inhibitors for improved drug efficacy.
